These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30052825)

  • 1. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation.
    Camm AJ; Dorian P; Hohnloser SH; Kowey PR; Tyl B; Ni Y; Vandzhura V; Maison-Blanche P; de Melis M; Sanders P
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):21-28. PubMed ID: 30052825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy.
    Shunmugam SR; Sugihara C; Freemantle N; Round P; Furniss S; Sulke N
    J Interv Card Electrophysiol; 2018 Apr; 51(3):191-197. PubMed ID: 29460236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation.
    Podd SJ; Freemantle N; Furniss SS; Sulke N
    Europace; 2016 Mar; 18(3):340-6. PubMed ID: 26462707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
    Piccini JP; Pritchett EL; Davison BA; Cotter G; Wiener LE; Koch G; Feld G; Waldo A; van Gelder IC; Camm AJ; Kowey PR; Iwashita J; Dittrich HC
    Heart Rhythm; 2016 Sep; 13(9):1777-83. PubMed ID: 27108936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
    Reiffel JA; Camm AJ; Belardinelli L; Zeng D; Karwatowska-Prokopczuk E; Olmsted A; Zareba W; Rosero S; Kowey P;
    Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1048-56. PubMed ID: 26226999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
    J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxysmal atrial fibrillation burden before and after pulmonary veins isolation: an observational study through a subcutaneous leadless cardiac monitor.
    Pedrote A; Arana-Rueda E; García-Riesco L; Sánchez-Brotons J; Durán-Guerrero M; Gómez-Pulido F; Arce-León A; Frutos-López M
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1075-82. PubMed ID: 23790041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.
    Macchia A; Grancelli H; Varini S; Nul D; Laffaye N; Mariani J; Ferrante D; Badra R; Figal J; Ramos S; Tognoni G; Doval HC;
    J Am Coll Cardiol; 2013 Jan; 61(4):463-468. PubMed ID: 23265344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation.
    Pokushalov E; Romanov A; De Melis M; Artyomenko S; Baranova V; Losik D; Bairamova S; Karaskov A; Mittal S; Steinberg JS
    Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):754-60. PubMed ID: 23748210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial.
    Ad N; Holmes SD; Shuman DJ; Pritchard G; Miller CE
    J Thorac Cardiovasc Surg; 2016 Mar; 151(3):798-803. PubMed ID: 26253874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.
    Ezekowitz MD; Ellenbogen KA; DiMarco JP; Kaszala K; Boddy A; Geba GP; Koren A
    J Interv Card Electrophysiol; 2015 Mar; 42(2):69-76. PubMed ID: 25638303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of drug-related morphological changes of the T wave.
    Tjäderborn M; Aunes-Jansson M; Samuelsson E; Frison L; Johansson S; Berggren A; Edvardsson N
    Scand Cardiovasc J; 2010 Aug; 44(4):215-22. PubMed ID: 20429697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
    Goette A; Schön N; Kirchhof P; Breithardt G; Fetsch T; Häusler KG; Klein HU; Steinbeck G; Wegscheider K; Meinertz T
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):43-51. PubMed ID: 22157519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation (MAGIC-AF) Study: clinical background and study design.
    Singh SM; D'Avila A; Kim YH; Aryana A; Mangrum JM; Michaud GF; Dukkipati SR; Callans DJ; Barrett CD; Beras-Jovine MR; Reddy VY
    J Cardiovasc Electrophysiol; 2012 Apr; 23(4):352-8. PubMed ID: 22034996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial.
    Raatikainen MJ; Hakalahti A; Uusimaa P; Nielsen JC; Johannessen A; Hindricks G; Walfridsson H; Pehrson S; Englund A; Hartikainen J; Kongstad O; Mortensen LS; Hansen PS;
    Int J Cardiol; 2015 Nov; 198():108-14. PubMed ID: 26163901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
    Maciag A; Farkowski MM; Chwyczko T; Beckowski M; Syska P; Kowalik I; Pytkowski M; Wozniak J; Dabrowski R; Szwed H
    Europace; 2017 Oct; 19(10):1637-1642. PubMed ID: 28339554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relations between baseline burden, maximum duration, and relative reduction of atrial fibrillation: Insights from continuous monitoring in rhythm control.
    Lin PL; Huang CC; Wu YJ; Su MI; Chiou WR; Liu LY; Liao FC; Lai E; Chen CY; Kuo JY; Lee YH
    J Cardiovasc Electrophysiol; 2019 Feb; 30(2):178-182. PubMed ID: 30575199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of antiarrhythmic drugs to maintain sinus rhythm after catheter ablation for atrial fibrillation: a meta-analysis.
    Xu X; Alida CT; Yu B
    Cardiovasc Ther; 2015 Aug; 33(4):242-6. PubMed ID: 26031448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.